Literature DB >> 11879577

Morphologic change and elevation of cortisol secretion in cultured human normal adrenocortical cells caused by mutant p21K-ras protein.

Chia-Hung Wu1, Su-Chen Lee, Hua-Hsien Chiu, Yuan-Chieh Yang, Shen-Tsuen Lian, Shyi-Jang Shin, Shiu-Ru Lin.   

Abstract

In our previous study on the tumorigenesis of human functional adrenal tumors, we observed a high frequency of K-ras point mutations in clinical specimens. Furthermore, we cloned the mutated K-ras gene from the tumors and inserted it into vectors to transfect normal bovine adrenocortical cells to express the mutated K-ras gene. The mRNA level of steroidogenic enzymes such as cholesterol sidechain cleavage enzyme (P450SCC), 17alpha-hydroxylase/17,20-lyase (P450c17), and 3beta-hydroxysteroid dehydrogenase (3betaHSD) in the mutant K-ras stably transfected cells were elevated. Cultured normal adrenocortical cells from donors and patients with adrenocortical tumors were then transfected with mutant K-ras expression plasmids constructed from human adrenal tumors. Stable transfectants grew faster than normal cells. Additionally, morphologic change was observed in the transfected cells. Moreover, when the synthesis of hormones was analyzed, the mRNA of P450SCC, P450C17, and 3betaHSD was found to have increased, and the level of cortisol was 18 to 25 times that in control cells. The increased steroid hormone production in mutant K-ras-transfected cells was reversed by lovastatin, a pharmacologic inhibitor of p21ras function. These results, combined with previous reports of steroidogenic K-ras in bovine adrenocortical cells, suggest that the K-ras oncogene is involved in steroidogenesis in human adrenocortical cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11879577     DOI: 10.1089/10445490252810285

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  6 in total

1.  Simvastatin reduces steroidogenesis by inhibiting Cyp17a1 gene expression in rat ovarian theca-interstitial cells.

Authors:  Israel Ortega; Amanda B Cress; Donna H Wong; Jesus A Villanueva; Anna Sokalska; Ben C Moeller; Scott D Stanley; Antoni J Duleba
Journal:  Biol Reprod       Date:  2012-01-30       Impact factor: 4.285

2.  Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance.

Authors:  O Celik; O Acbay
Journal:  J Endocrinol Invest       Date:  2012-04-18       Impact factor: 4.256

3.  Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip.

Authors:  Ming-Yii Huang; Hsueh-Chiao Liu; Li-Chen Yen; Jia-Yuan Chang; Jian-Jhang Huang; Jaw-Yuan Wang; Shiu-Ru Lin
Journal:  Tumour Biol       Date:  2014-06-27

Review 4.  HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome?

Authors:  Pinar H Kodaman; Antoni J Duleba
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  Statins in the treatment of polycystic ovary syndrome.

Authors:  Pinar H Kodaman; Antoni J Duleba
Journal:  Semin Reprod Med       Date:  2008-01       Impact factor: 1.303

6.  Mutant K-ras oncogene regulates steroidogenesis of normal human adrenocortical cells by the RAF-MEK-MAPK pathway.

Authors:  C-H Wu; Y-F Chen; J-Y Wang; M-C Hsieh; C-S Yeh; S-T Lian; S-J Shin; S-R Lin
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.